Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors

NCT06032845 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06032845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06032845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Evaluate the Efficacy and Safety of Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
September 13, 2023
Completion date
December 30, 2025
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult